News

Medindia5mon
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) - Medindia
AVT05 is a biosimilar candidate for Simponi ® and Simponi Aria ® (golimumab). Golimumab is a monoclonal antibody that inhibits tumor necrosis factor alpha (TNF alpha).
The Globe and Mail5mon
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria ... - The Globe and Mail
About AVT05 AVT05 is a biosimilar candidate for Simponi ® and Simponi Aria ® (golimumab). Golimumab is a monoclonal antibody that inhibits tumor necrosis factor alpha (TNF alpha).
Taiwan News5mon
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
In August 2020, Alvotech and Teva entered into a strategic partnership for the exclusive commercialization of five of Alvotech’s biosimilar product candidates, including AVT05. The partnership has ...
Nasdaq5mon
Alvotech: FDA To Review BLA For AVT05 - Quick Facts - Nasdaq
In 2020, Alvotech and Teva entered into a strategic partnership for the exclusive commercialization of five of Alvotechs biosimilar product candidates, including AVT05. Since the companies entered ...
Nasdaq8mon
Alvotech’s AVT05 Biosimilar Application Accepted by EMA
Alvotech (ALVO) has released an update.Alvotech, in collaboration with Advanz Pharma, has announced the acceptance of its Marketing Authorization Application for AVT05, a proposed biosimilar to ...
Stockhouse8mon
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - Stockhouse
About AVT05 AVT05 is a biosimilar candidate for Simponi ® and Simponi Aria ® (golimumab). Golimumab is a monoclonal antibody that inhibits tumor necrosis factor alpha (TNF alpha).
WRIC8mon
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - WRIC ABC 8News
About AVT05 AVT05 is a biosimilar candidate for Simponi ® and Simponi Aria ® (golimumab). Golimumab is a monoclonal antibody that inhibits tumor necrosis factor alpha (TNF alpha).